Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
- PMID: 12813170
- DOI: 10.1093/jnci/95.12.868
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
Abstract
Background: Screening for prostate cancer advances the time of diagnosis (lead time) and detects cancers that would not have been diagnosed in the absence of screening (overdetection). Both consequences have considerable impact on the net benefits of screening.
Methods: We developed simulation models based on results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC), which enrolled 42,376 men and in which 1498 cases of prostate cancer were identified, and on baseline prostate cancer incidence and stage distribution data. The models were used to predict mean lead times, overdetection rates, and ranges (corresponding to approximate 95% confidence intervals) associated with different screening programs.
Results: Mean lead times and rates of overdetection depended on a man's age at screening. For a single screening test at age 55, the estimated mean lead time was 12.3 years (range = 11.6-14.1 years) and the overdetection rate was 27% (range = 24%-37%); at age 75, the estimates were 6.0 years (range = 5.8-6.3 years) and 56% (range = 53%-61%), respectively. For a screening program with a 4-year screening interval from age 55 to 67, the estimated mean lead time was 11.2 years (range = 10.8-12.1 years), and the overdetection rate was 48% (range = 44%-55%). This screening program raised the lifetime risk of a prostate cancer diagnosis from 6.4% to 10.6%, a relative increase of 65% (range = 56%-87%). In annual screening from age 55 to 67, the estimated overdetection rate was 50% (range = 46%-57%) and the lifetime prostate cancer risk was increased by 80% (range = 69%-116%). Extending annual or quadrennial screening to the age of 75 would result in at least two cases of overdetection for every clinically relevant cancer detected.
Conclusions: These model-based lead-time estimates support a prostate cancer screening interval of more than 1 year.
Comment in
-
Simulated screening for prostate cancer: the useful model.J Natl Cancer Inst. 2003 Jun 18;95(12):838-9. doi: 10.1093/jnci/95.12.838. J Natl Cancer Inst. 2003. PMID: 12813160 No abstract available.
Similar articles
-
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10. J Natl Cancer Inst. 2009. PMID: 19276453 Free PMC article.
-
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.J Natl Cancer Inst. 2007 Sep 5;99(17):1296-303. doi: 10.1093/jnci/djm101. Epub 2007 Aug 28. J Natl Cancer Inst. 2007. PMID: 17728218 Clinical Trial.
-
Screening for prostate cancer: estimating the magnitude of overdetection.CMAJ. 1998 Dec 1;159(11):1368-72. CMAJ. 1998. PMID: 9861205 Free PMC article.
-
Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Can J Urol. 2005. PMID: 15780157 Review.
-
Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?Ann Clin Biochem. 2011 Jul;48(Pt 4):310-6. doi: 10.1258/acb.2011.010273. Epub 2011 Apr 27. Ann Clin Biochem. 2011. PMID: 21525152 Review.
Cited by
-
Risk-based prostate cancer screening.Eur Urol. 2012 Apr;61(4):652-61. doi: 10.1016/j.eururo.2011.11.029. Epub 2011 Nov 24. Eur Urol. 2012. PMID: 22134009 Free PMC article. Review.
-
Ethnicity and prostate cancer: the way to solve the screening problem?BMC Med. 2015 Aug 4;13:179. doi: 10.1186/s12916-015-0427-z. BMC Med. 2015. PMID: 26239718 Free PMC article.
-
Manipulating the epigenome for the treatment of urological malignancies.Pharmacol Ther. 2013 May;138(2):185-96. doi: 10.1016/j.pharmthera.2013.01.007. Epub 2013 Jan 24. Pharmacol Ther. 2013. PMID: 23353098 Free PMC article. Review.
-
Simulation optimization of PSA-threshold based prostate cancer screening policies.Health Care Manag Sci. 2012 Dec;15(4):293-309. doi: 10.1007/s10729-012-9195-x. Health Care Manag Sci. 2012. PMID: 22302420 Free PMC article.
-
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.Expert Rev Mol Diagn. 2015 May;15(5):647-64. doi: 10.1586/14737159.2015.1027194. Epub 2015 Mar 22. Expert Rev Mol Diagn. 2015. PMID: 25797072 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical